Salud reinforces the use of artificial intelligence in the improvement of diagnosis and treatment of various diseases

El Servicio Navarro de Salud-Osasunbidea reinforces its commitment to the utilization of artificial intelligence in health care, with various initiatives for treatment and diagnosis of diseases. This Friday will be presented in the HUN, inside the “II Days of Innovation, Evaluation and Diffusion of Results in Health”.

The most immediate implantation of this technology in the Navarro Health-Osasunbidea Service will be for the treatment of Age-Associated Macular Degeneration (DMAE), which will be added to the existing one for the diagnosis of Diabetic Retinopathy, and which will have continuity en un futuro próximo en otras aplicaciones relacionados con la Dermatology y la Radiología. The development of these applications is carried out by the technical staff of the Service of Health Technologies of the Directorate General of Telecommunications and Digitalization, in collaboration with the Sub-Direction of Information Systems of the SNS-O and the clinical services involved.

The application NaIA-DMAE, whose launch is foreseen for the first trimester of 2023, will allow, through the use of artificial intelligence in Age-Associated Macular Degeneration, to predict the evolution of this disease in each patient, making it possible the personalization of the treatment más adequate in each case with a considerable saving of time.

Likewise, it is expected that this technological strategy will have continuity in other programs that also involve artificial intelligence in health, such as NaIA Dermatology and NaIA Bone Radiology, in aspects very related to collaboration circuits between Primary and Hospital Attention, with a high potential for diminuir derivaciones de pacientes y por lo tanto, listas de espera. Estos proyectos se unen así al programa NaIA-Retinopatía Diabética, en funcionamiento desde 2020, y cuyos resultados proparicaron recentente al SNS-O una distinción nacional de gestion sanitaria.

The use of artificial intelligence as an auxiliary tool for making clinical decisions constitutes one of the points around which the “II Days of Innovation, Evaluation and Diffusion of Results in Health” will be held, which, under the motto “Recopilando el conocimiento”, van a celebrarse en el hall de actos B del Hospital Universitario de Navarra (HUN) los días 21 y 28 de este mes, con el objetivo de fundir entre los cadres directorivos y profesionales del SNS-O experiencias en innovation e initiativas que se han ido desarrollando para evaluar y difundir los resultados en salud, optimizar su uso y detecter nuevas necessidades.

Principal causa de pérdida visual irreversible in población de mayor edad

Age-Associated Macular Degeneration (DMAE) is the most important cause of irreversible visual loss in the elderly population in Navarre and constitutes the main reason for citation by the Ophthalmology Service. The volume of patients increases every time due to the aging of the population.

En cada consulta sobre esta dolencia, al paciente se le mide la agudeza visual y se le realiza una Tomografía de Hererencia Óptica, prueba formeda por 50 imágenes, 25 por cada ojo. El oftalmólogo debe valorar a contado la tomografía de ese día y revisar las previouses para decidir si procede una nueva dosis del pharmaco para tratar esta dolencia, que se administra mediate una injección en la retina, y programar una nueva visita. Given the limited time of the consultation, it is very complicated to value the revision of all the previous tests, so the decision on the administration of the drug tends to be based on the evolution of the most recent ones.

NaIA-DMAE analyzes all tomographies and generates a series of measurements (known as biomarkers) on harmful liquids present in the retina, which are stored in the Historia Clínica Informatizada (HCI). Through the use of these biomarkers, HCI generates a graph that represents the response to treatment in each patient.

This information, available at the same moment of consultation, allows for better informed decisions, much faster and more objective, based on measurements.

Jornadas sobre transformación tecnologia, gestioni y análisis

The “II Jornadas de Innovation, Evaluación y difusión de resultados en Salud” will, over the course of two days, demonstrate the main experiences in technological transformation, management and data analysis in the different work areas of the Navarro Health-Osasunbidea Service.

The presentations on the application of artificial intelligence in the SNS-O will take place on October 21, together with two other sessions, one dedicated to other collaborations between the Directorate General of Telecommunications and Digitalization and the Department of Health, and the second on experiencias de innovation en los sistemas de información sanitaria.

On the second day, on the 28th, the topics will be the evaluation of results in clinical practice, the use of analytical accounting for decision making and research, and advanced statistical analyses.

.

Leave a Comment

Your email address will not be published. Required fields are marked *